Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Current Liabilities: 2021-2025

Historic Total Current Liabilities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $50.9 million.

  • ARS Pharmaceuticals' Total Current Liabilities rose 206.06% to $50.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.9 million, marking a year-over-year increase of 206.06%. This contributed to the annual value of $23.4 million for FY2024, which is 880.34% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Total Current Liabilities is $50.9 million, which was up 11.57% from $45.6 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Total Current Liabilities ranged from a high of $50.9 million in Q3 2025 and a low of $2.4 million during Q4 2023.
  • Moreover, its 3-year median value for Total Current Liabilities was $11.2 million (2023), whereas its average is $18.9 million.
  • In the last 5 years, ARS Pharmaceuticals' Total Current Liabilities tumbled by 74.00% in 2022 and then surged by 880.34% in 2024.
  • Quarterly analysis of 5 years shows ARS Pharmaceuticals' Total Current Liabilities stood at $8.2 million in 2021, then plummeted by 33.50% to $5.4 million in 2022, then slumped by 56.08% to $2.4 million in 2023, then surged by 880.34% to $23.4 million in 2024, then skyrocketed by 206.06% to $50.9 million in 2025.
  • Its last three reported values are $50.9 million in Q3 2025, $45.6 million for Q2 2025, and $27.6 million during Q1 2025.